Evidence map›Paper›PMID 36839460›Full record

ArticlePathogens (Basel, Switzerland)2023

Development of an Orthotopic HPV16-Dependent Base of Tongue Tumor Model in MHC-Humanized Mice.

Christoph Schifflers, Samantha Zottnick, Jonas D Förster, Sebastian Kruse, Ruwen Yang, Hendrik Wiethoff, Matthias Bozza, Karin Hoppe-Seyler, Mathias Heikenwälder, Richard P Harbottle and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Christoph SchifflersImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-2266-8621
Samantha ZottnickImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-9077-635X
Jonas D FörsterImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0003-3437-6738
Sebastian KruseImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-4028-1391
Ruwen YangViral Transformation Mechanisms, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-2890-6475
Hendrik WiethoffInstitute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.ORCID 0000-0002-8450-653X
Matthias BozzaDNA Vector Laboratory, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Karin Hoppe-SeylerMolecular Therapy of Virus-Associated Cancers, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Mathias HeikenwälderChronic Inflammation and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Richard P HarbottleDNA Vector Laboratory, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Carine MichielsCell Biology Research Unit (URBC)-Namur Research Institute for Life Sciences (NARILIS), University of Namur, 5000 Namur, Belgium.ORCID 0000-0002-9169-1294
Angelika B RiemerImmunotherapy and Immunoprevention, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.ORCID 0000-0002-5865-0714
German Cancer Research Center · DEUniversity of Namur · BE

Funding

Fonds National de la Recherche Scientifique - Télévie Fellowship to Christoph Schifflers, 34950111German Cancer Research Center Helmholtz International Graduate School Ph.D. scholarship to Samatha Zottnick
6 · The paper itself

Abstract

Head and neck squamous cell carcinomas (HNSCC) caused by infections with high-risk human papillomaviruses (HPV) are responsible for an increasing number of head and neck cancers, particularly in the oropharynx. Despite the significant biological differences between HPV-driven and HPV-negative HNSCC, treatment strategies are similar and not HPV targeted. HPV-driven HNSCC are known to be more sensitive to treatment, particularly to radiotherapy, which is at least partially due to HPV-induced immunogenicity. The development of novel therapeutic strategies that are specific for HPV-driven cancers requires tumor models that reflect as closely as possible the characteristics and complexity of human tumors and their response to treatment. Current HPV-positive cancer models lack one or more hallmarks of their human counterpart. This study presents the development of a new HPV16 oncoprotein-dependent tumor model in MHC-humanized mice, modeling the major biologic features of HPV-driven tumors and presenting HLA-A2-restricted HPV16 epitopes. Furthermore, this model was developed to be orthotopic (base of tongue). Thus, it also reflects the correct tumor microenvironment of HPV-driven HNSCC. The cancer cells are implanted in a manner that allows the exact control of the anatomical location of the developing tumor, thereby homogenizing tumor growth. In conclusion, the new model is suited to study HPV16-specific therapeutic vaccinations and other immunotherapies, as well as tumor-targeted interventions, such as surgery or radiotherapy, or a combination of all these modalities.

Indexed as

head and neck squamous cell carcinomahuman papillomavirusorthotopic tumor model

Identifiers

PMID36839460
PMCPMC9958775
OpenAlexW4318053913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.